Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma (NCT05083754)
A Randomized, Open-label Pilot Trial to Evaluate the Safety and Efficacy of Carmustine Wafer in Combination With Retifanlimab and Standard Radiation With or Without Temozolomide in Newly-Diagnosed Adult Subjects With Glioblastoma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to evaluate the safety and survival of carmustine wafers and radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult subjects with glioblastoma multiform after carmustine wafer placement.
Who can join: Review the eligibility criteria below.
Location: Johns Hopkins Medical Institution — Baltimore, Maryland
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Johns Hopkins Medical Institution — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (410) 614-2597
Email: kleinla@jhmi.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Glioblastoma Multiforme
- A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme — Iowa City, Iowa
- Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) — Baltimore, Maryland
- Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme — Washington D.C., District of Columbia
- A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM — Tucson, Arizona
- Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients — Phoenix, Arizona
- Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM — Stanford, California
Explore by condition: All Glioblastoma Multiforme clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.